COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · Real-Time Price · USD
2.530
+0.180 (7.66%)
At close: Jun 24, 2025, 4:00 PM
2.588
+0.058 (2.31%)
After-hours: Jun 24, 2025, 7:59 PM EDT
COMPASS Pathways Employees
COMPASS Pathways had 166 employees as of December 31, 2024. The number of employees decreased by 20 or -10.75% compared to the previous year.
Employees
166
Change (1Y)
-20
Growth (1Y)
-10.75%
Revenue / Employee
n/a
Profits / Employee
-$830,114
Market Cap
236.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 166 | -20 | -10.75% |
| Dec 31, 2023 | 186 | 5 | 2.76% |
| Dec 31, 2022 | 181 | 65 | 56.03% |
| Dec 31, 2021 | 116 | 54 | 87.10% |
| Dec 31, 2020 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CMPS News
- 12 hours ago - Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360 - Seeking Alpha
- 1 day ago - Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 1 day ago - Compass Pathways stock slip as psilocybin depression trial falls short of expectations - Invezz
- 1 day ago - Compass Pathways' depression drug succeeds late-stage trial - Reuters
- 1 day ago - Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression - Business Wire
- 5 weeks ago - Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference - Business Wire
- 6 weeks ago - COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights - Business Wire